New pill combo aims to improve leukemia control without chemo

NCT ID NCT06637501

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the combo leads to more complete remissions and undetectable cancer levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aoor Villa Sofia Cervello

    Palermo, 90146, Italy

  • Aou Careggi, Servizio Sanitario Toscana

    Florence, 50134, Italy

  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

    Brescia, 25123, Italy

  • Centro de Pesquisas Oncologicas Cepon

    Florianópolis, 88034-000, Brazil

  • Cleveland Clinic Florida

    Weston, Florida, 33331-3609, United States

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350001, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Hospital de Cabuenes

    Gijón, 33394, Spain

  • Hospital de Clinicas de Porto Alegre

    Porto AlegreRS, 900350-903, Brazil

  • Illinois Cancer Specialists (Niles) Usor

    Niles, Illinois, 60714-5905, United States

  • Instituto Dor de Pesquisa E Ensino Sao Paulo

    São Paulo, 01401-004, Brazil

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Nebraska Cancer Specialists

    Omaha, Nebraska, 68130-2042, United States

  • Nebraska Cancer Specialists (Satellite Site)

    Omaha, Nebraska, 68130-2042, United States

  • Northwest Georgia Oncology Centers Marietta

    Marietta, Georgia, 30060-1152, United States

  • Oncology Associates of Oregon Willamette Valley Cancer Center

    Eugene, Oregon, 97401, United States

  • Pratia McM Krakow

    Krakow, 30-727, Poland

  • Pratia Onkologia Katowice

    Katowice, 40-519, Poland

  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, 05652-900, Brazil

  • Texas Oncology Dfw

    Dallas, Texas, 75231-7001, United States

  • Texas Oncology Tyler

    Tyler, Texas, 75702-7522, United States

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • The First Peoples Hospital of Changzhou

    Changzhou, Jiangsu, 213000, China

  • The University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland, 21201, United States

  • Universita Degli Studi Di Modena Azienda Ospedaliere Policlinco

    Modena, 41124, Italy

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu

    Wroclaw, 50-367, Poland

  • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie

    Lublin, 20-090, Poland

  • Utah Cancer Specialists Cancer Center

    Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.